Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose

06/17/2021 | 04:05pm EDT

By Kim Mackrael

OTTAWA--A Canadian vaccine panel said Thursday that people who received a first dose of AstraZeneca PLC's vaccine against Covid-19 should get a different vaccine for their second dose.

Canada's national advisory panel on immunization said earlier this month that authorized Covid-19 vaccines could be mixed, and noted some people might prefer to get a messenger RNA vaccine for their second shot. The panel has previously said mRNA vaccines, such as the ones produced by Pfizer Inc. in partnership with BioNTech SE, as well as Moderna Inc., are preferable to viral vector vaccines, such as those developed by AstraZeneca and Johnson & Johnson.

On Thursday, it changed its advice to recommend against the use of AstraZeneca's vaccine in most cases.

"An mRNA vaccine should now be offered as the second dose for individuals who received a first dose" of AstraZeneca's vaccine, said Dr. Howard Njoo, Canada's deputy chief public health officer. People who are getting their first vaccine dose should also be offered an mRNA vaccine unless they have a contraindication or none of those vaccines are available, he said.

Dr. Njoo said the advisory panel's advice is based on emerging evidence that shows a potentially better immune response from a mixed vaccine schedule, and concerns about blood clotting associated with the AstraZeneca vaccine. Another factor the advisory panel considered is the increased availability of mRNA vaccines in Canada, he said.

The panel's recommendations aren't binding, but tend to be followed by provinces in Canada, which are responsible for delivering health care.

After a sluggish start earlier in the year, Canada has sharply increased its administration of Covid-19 vaccines in recent months. Nearly 66% of the population had received at least one dose of a Covid-19 vaccine as of June 16, although just 15% of the population is fully vaccinated.

Write to Kim Mackrael at kim.mackrael@wsj.com

(END) Dow Jones Newswires

06-17-21 1805ET

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.33% 8270 Delayed Quote.13.29%
BIONTECH SE 17.80% 414.44 Delayed Quote.331.56%
JOHNSON & JOHNSON -0.59% 173.36 Delayed Quote.10.81%
MODERNA, INC. 8.42% 419.05 Delayed Quote.269.97%
PFIZER, INC. -1.07% 45.19 Delayed Quote.24.10%
All news about ASTRAZENECA PLC
12:33pASTRAZENECA : SVB Leerink Adjusts Price Target on AstraZeneca to $69 From $63, M..
08:38aASTRAZENECA : Japan to ship total of 1.6 mil. COVID vaccine doses to Nepal
03:10aThai hospital tycoon who promised Pfizer vaccine says deal now unlikely
08/03ASTRAZENECA : Chilean study shows variations in success of COVID-19 vaccines
08/03THE LATEST : NYC: Vaccination proof for indoor dining, gyms
08/03ASTRAZENECA : SAPHNELO approved in the US for moderate to severe systemic lupus ..
08/03ASTRAZENECA : Sanwo-Olu - Lagos Recorded 4,300 Cases, 30 Fatalities in July
08/03ASTRAZENECA : Covid-19 Third Wave - Lagos Records 42 Deaths in One Week - Sanwo-..
08/02Fancy a Covid jab? Here are all the free walk-in sites open in London
08/02U.S. Food and Drug Administration Approves AstraZeneca PLC's SaphneloÖ (Anifr..
More news
Financials (USD)
Sales 2021 35 164 M - -
Net income 2021 5 236 M - -
Net Debt 2021 25 946 M - -
P/E ratio 2021 21,8x
Yield 2021 3,41%
Capitalization 128 B 178 B -
EV / Sales 2021 4,38x
EV / Sales 2022 3,53x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 82,70 $
Average target price 133,83 $
Spread / Average Target 61,8%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.29%178 598
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
NOVARTIS AG-0.20%224 638